Identifying Most Effective Treatment Strategies to Control Arterial Hypertension in Sub-Saharan Africa (coArtHA)
Arterial Hypertension

About this trial
This is an interventional other trial for Arterial Hypertension focused on measuring antihypertensive treatment
Eligibility Criteria
Inclusion Criteria:
- HIV-positive and negative patients of African descent and black ethnicity with a documented uncomplicated, untreated arterial hypertension (blood pressure >/=140/90 mmHg) diagnosed at one of the 2 study sites
Exclusion Criteria:
- Current hospitalization for any reason
- Not of African descent
- Refusal of an HIV-test or indeterminate HIV test result
- History of cardiovascular event in the last month (anginal pain, stroke, myocardial infarction or diagnosis by a doctor)
- Symptomatic arterial hypertension (blood pressure >/=180/110 mmHg plus headache or chest pain) or acute cardiovascular event
- acute disease, (e.g. fever >37.5°C or other signs of acute concomitant infection; Dyspnea/respiratory distress; Acute pain)
- Clinical signs of hypertension-mediated organ damage (heart failure, bilateral pitting edema, bilateral crackles or pleural effusion, distended jugular veins, ischemic heart disease (anginal pain on exertion), signs of current ischemic/hemorrhagic stroke (hemiparesis, loss of consciousness)
- Pregnancy (test required for females 18-45years of age)
- Non-consenting or inability to come for follow-up visits
- creatinine clearance </=30ml/min by Chronic Kidney Disease Epidemiology Formula (CK-EPI) estimation and measurement with a point-of care creatinine from capillary blood
Sites / Locations
- SolidarMed Lesotho, Mokhotlong Government Hospital
- Division of Infectious Diseases & Hospital Epidemiology; University Hospital Basel
- St. Francis Referral Hospital/ Ifakara Health Institute
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Placebo Comparator
Intervention 1: dual combination
Intervention 2: triple combination
Standard of care
dual combination of half-dose Calcium Channel Blocker (CCB) and Angiotensin II Receptor Blocker (ARB), dosage increases at 4 and 8 weeks if target blood pressure is not reached at the respective time point
triple combination of quarter-dose of Calcium Channel Blocker (CCB), Thiazide diuretic (TZD) and Angiotensin II Receptor Blocker (ARB) with dosage increases of all drugs at 4 and 8 weeks, if target blood pressure is not reached at the respective time point
start normal dose Calcium Channel Blocker (CCB), add Thiazide diuretic (TZD) after 4weeks and increase of TZD dosage after 8 weeks, if target blood pressure is not reached at the respective time point